2-(6-methyl-pyridin-3-yloxy)-ethylamine | 850420-89-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(6-methyl-pyridin-3-yloxy)-ethylamine
• 英文别名: 2-[(6-Methylpyridin-3-yl)oxy]ethan-1-amine；2-(6-methylpyridin-3-yl)oxyethanamine
• CAS: 850420-89-2
• 化学式: C₈H₁₂N₂O
• 分子量: 152.196
• InChiKey: FBZDITRTMIREDT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-chloro-6-(5-methyl-1H-pyrazol-3-ylamino)-4-methylnicotinonitrile 、 2-(6-methyl-pyridin-3-yloxy)-ethylamine 在 碳酸氢钠 作用下， 以 二甲基亚砜 为溶剂， 生成 2-(2-(6-methylpyridin-3-yloxy)ethylamino)-6-(5-methyl-1H-pyrazol-3-ylamino)-4-methylnicotinonitrile
  参考文献：
  名称：

  3-氰基-6-（5-甲基-3-吡唑并氨基）吡啶（第2部分）：极光激酶和微管蛋白聚合的双重抑制剂。

  摘要：

  通过将各种取代的苯氧基乙基氨基或吡啶基氧基乙基氨基基团引入3-氰基-4-甲基-6-（5-甲基-3-吡唑并氨基）-吡啶的2-位基团，创建了新型的Aurora激酶和微管蛋白聚合的双重抑制剂。与其他66种激酶相比，化合物3g表现出Aurora激酶抑制作用，对Aurora激酶具有优异的蛋白激酶选择性，组蛋白H3作为Aurora激酶抑制剂的组蛋白H3的Ser10磷酸化得到抑制，在体外抑制微管蛋白聚合，良好的细胞膜通透性和良好的抑制作用。 PK配置文件。因此，化合物3g在某些抗肿瘤小鼠模型中以30mg / kgpoqd的剂量有效。

  DOI：

  10.1016/j.bmcl.2016.11.020

文献信息

• RING-FUSED 2-PYRIDONE DERIVATIVES AND HERBICIDES
  申请人：Takabe Fumiaki

  公开号：US20110287937A1

  公开（公告）日：2011-11-24

  Provided are 2-pyridone derivatives which have excellent herbicidal activity and exhibit high safety to useful crops and so on; salts thereof; and herbicides containing same. In more detail, 2-pyridone derivatives represented by general formula [I] or agrochemically acceptable salts thereof, and herbicides containing these compounds are provided. In general formula [I], X 1 is an oxygen atom or a sulfur atom; X 2 , X 3 , and X 4 are to each CH or N(O) m ; m is an integer of 0 or 1; R 1 is a hydrogen atom, a C 1-12 alkyl group, or the like; R 2 is a halogen atom, a cyano group, or the like; n is an integer of 0 to 4; R 3 is a hydroxyl group, a halogen atom, or the like; A 1 is C(R 11 R 12 ); A 2 is C(R 13 R 14 ) or C═O; A 3 is C(R 15 R 16 ); and R 11 , R 12 , R 13 , R 14 , R 15 , and R 16 are each independently a hydrogen atom or a C 1-6 alkyl group.

  提供了具有优异除草活性并对有用作物等表现出高安全性的2-吡啶酮衍生物；其盐；以及含有这些化合物的除草剂。更详细地说，提供了通式[I]所表示的2-吡啶酮衍生物或其农药可接受的盐，以及含有这些化合物的除草剂。在通式[I]中，X1是氧原子或硫原子；X2、X3和X4分别为CH或N(O)m；m是0或1的整数；R1是氢原子，C1-12烷基或类似物；R2是卤素原子，氰基或类似物；n是0到4的整数；R3是羟基，卤素原子或类似物；A1是C(R11R12)；A2是C(R13R14)或C═O；A3是C(R15R16)；R11、R12、R13、R14、R15和R16分别独立地是氢原子或C1-6烷基基团。
• Substituted 2H-[1,2,4]Triazolo[4,3-A]Pyrazines as Gsk-3 Inhibitors
  申请人：Benbow William John

  公开号：US20070249612A1

  公开（公告）日：2007-10-25

  The invention relates to compounds of formula (I) prodrugs thereof, and the pharmaceutically acceptable salts of the compounds and prodrugs, wherein R a , R b , R 1 and R 2 are as defined herein; pharmaceutical compositions thereof; and uses thereof.

  本发明涉及公式(I)化合物及其前药、所述化合物和前药的药学上可接受的盐，其中Ra、Rb、R1和R2如本文所定义；药物组合物；以及其用途。
• Tetrasubstituted alkene compounds and their use
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US10851065B2

  公开（公告）日：2020-12-01

  Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

  本文公开了化合物或其药学上可接受的盐类，以及通过向需要治疗的对象施用治疗有效量的化合物或其药学上可接受的盐类来使用这些化合物治疗乳腺癌的方法。乳腺癌可以是ER阳性乳腺癌和/或需要治疗的受试者可以表达突变的ER-α蛋白。
• SUBSTITUTED 2H-[1,2,4]TRIAZOLO 4,3-A PYRAZINES AS GSK-3 INHIBITORS
  申请人：Pfizer Products Incorporated

  公开号：EP1678180B1

  公开（公告）日：2007-08-08
• TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US20180127378A1

  公开（公告）日：2018-05-10

  Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.